HEPATIC DIRECTED ANTIVIRAL AGENTS

Award Information
Agency:
Department of Health and Human Services
Branch:
N/A
Amount:
$50,000.00
Award Year:
1992
Program:
SBIR
Phase:
Phase I
Contract:
N/A
Agency Tracking Number:
18969
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Advanced Magnetics Inc
61 Mooney Street, Cambridge, MA, 02138
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
N/A
Principal Investigator
 Philip M Enriquez
 (617) 497-2070
Business Contact
Phone: () -
Research Institution
N/A
Abstract
THE OBJECT OF THIS RESEARCH IS TO DEVELOP AN ANTI-HEPATITIS B VIRUS PRO-DRUG WHICH WILL CONCENTRATE IN THE INFECTED LIVER TISSUE BY BINDING THE HEPATIC ASIALOGLYCOPROTEIN RECEPTOR AND RELEASING THE ACTIVE FORM OF THE DRUG IN THE HEPATOCYTE. TOWARD THIS END, A NUMBER OF ADENOSINE ARABINOFURANOSIDE/ARABINOGALACTAN CONJUGATES WILL BE SYNTHESIZED. THE CONJUGATES WILL BE EVALUATED AS SUITABLE PRODRUGS BY SEVERAL CRITICAL TESTS. INTERACTION WITH THE HEPATICASIALOGLYCOPROTEIN RECEPTOR IN VITRO WILL BE DETERMINED IN A COMPETITIVE BINDING ASSAY USING ISOLATED RAT HEPATOCYTES. THE RELEASE OF ADENOSINE ARABINOFURANOSIDE, OR IN SOME INSTANCES, ITS ALSO ACTIVE 5 MONOPHOSPHATE DERIVATIVE, WILL BE MEASURED IN VITRO ALSO USING A HEPATOCYTE CELL CULTURE A PRELIMINARY TOXICOLOGICAL EXAMINATION OF THE CONJUGATE CONSIDERED MOST SUITABLE AS A PRO-DRUG WILL BE CONDUCTED. THE RESEARCH IS EXPECTED TO LEAD TO AN ANTIVIRAL PRO-DRUG OF ADENOSINE ARABINOFURANOSIDE POSSESSING A GREATER POTENCY AND LOWERTOXICITY RELATIVE TO THE FREEDRUG.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government